핵산 분리 및 정제 시장 규모, 점유율과 동향 분석 보고서 : 제품별, 유형별, 용도별, 방법별, 최종 용도별, 지역별, 부문 예측(2026-2033년)

Nucleic Acid Isolation & Purification Market Summary

The global nucleic acid isolation and purification market size was valued at USD 6.05 billion in 2025 and is anticipated to reach USD 12.84 billion by 2033, growing at a CAGR of 10.07% from 2026 to 2033. The expansion is fueled by several factors, such as the rise in adoption of sequencing platforms for clinical diagnostics, growth in genomics & enzymology-based research, and an increase in investments in R&D.

In addition, the potential of molecular biology and advancement in precision medicine are further augmenting market growth. Increasing efforts of market participants to strengthen the manufacturing capacity are facilitating market expansion. The incidence of genetic disorders, cancer, and infectious diseases has been growing globally for the past few years. Disorders such as thalassemia, sickle cell anemia, and cystic fibrosis are caused by genetic aberrations in an individual's DNA. Studying nucleic acids helps gain insights into these diseases. The race for developing cost-effective, point-of-contact testing kits and efficient laboratory procedures for detecting COVID-19 infection has driven a new scope of diagnostic innovation. An increase in the adoption of PCR for SARS-CoV-2 detection by a broad range of commercial laboratories drives the market, as nucleic acid isolation & purification is a significant step in the PCR workflow.

The biotechnology industry is also marked by advancements and innovations. Diagnostic tests have become more cost-effective and easier to use. The companies are investing to advance the DNA isolation process. Furthermore, automated and advanced instruments have entered the market with faster, more consistent, and cleaner processes. For instance, Thermo Fisher Scientific offers an Automated Nucleic Acid Extraction Workstation that uses revolutionary magnetic separation technology.

Global Nucleic Acid Isolation And Purification Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global nucleic acid isolation and purification market report based on product, type, application, method, end-use, and region.

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Kits & reagents
• Instruments
  • Manual
  • Automatic
• Type Outlook (Revenue, USD Billion, 2021 - 2033)
• DNA Isolation & Purification
  • Genomic DNA isolation & purification
  • Plasmid DNA isolation & purification
  • Viral DNA isolation & purification
  • Other
• RNA Isolation & Purification
  • miRNA isolation & purification
  • mRNA isolation & purification
  • Total RNA isolation & purification
  • Other
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Precision medicine
• Diagnostics
• Drug discovery & development
• Agriculture and animal research
• Other applications
• Method Outlook (Revenue, USD Billion, 2021 - 2033)
• Column based
• Magnetic beads
• Reagent based
• Others
• End-use Outlook (Revenue, USD Billion, 2021 - 2033)
• Academic research institutes
• Pharmaceutical & biotechnology companies
• Contract research organizations
• Hospitals and diagnostic centers
• Other end-use
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Type
  • 1.2.3. Application
  • 1.2.4. Method
  • 1.2.5. End use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Nucleic Acid Isolation And Purification Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing incidence of cancer, genetic disorders, and infectious diseases
    • 3.2.1.2. Increase in public-private funding for biotechnology and life science research
    • 3.2.1.3. Advancements in automation
    • 3.2.1.4. Growth in NGS technologies
    • 3.2.1.5. Growing demand for genetically modified crops and organisms
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Expensive instruments and consequent low penetration in emerging countries
    • 3.2.2.2. Challenges related to the use of big data and bioinformatics
• 3.3. Industry Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Product Business Analysis

• 4.1. Segment Dashboard
• 4.2. Nucleic Acid Isolation and Purification Market: Product Movement Analysis
• 4.3. Kits & Reagents
  • 4.3.1. Kits & reagents market estimates and forecasts 2021 - 2033 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.2. Manual
    • 4.4.2.1. Manual market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.3. Automatic
    • 4.4.3.1. Automatic market estimates and forecasts 2021 - 2033 (USD Million)

Chapter 5. Type Business Analysis

• 5.1. Segment Dashboard
• 5.2. Nucleic Acid Isolation and Purification Market: Type Movement Analysis
• 5.3. DNA Isolation & Purification
  • 5.3.1. DNA isolation & purification market estimates and forecasts 2021 - 2033 (USD Million)
  • 5.3.2. Genomic DNA Isolation & Purification
    • 5.3.2.1. Genomic DNA isolation & purification market estimates and forecasts 2021 - 2033 (USD Million)
  • 5.3.3. Plasmid DNA Isolation & Purification
    • 5.3.3.1. Plasmid DNA isolation & purification market estimates and forecasts 2021 - 2033 (USD Million)
  • 5.3.4. Viral DNA Isolation & Purification
    • 5.3.4.1. Viral DNA isolation & purification market estimates and forecasts 2021 - 2033 (USD Million)
  • 5.3.5. Other
    • 5.3.5.1. Other market estimates and forecasts 2021 - 2033 (USD Million)
• 5.4. RNA Isolation & Purification
  • 5.4.1. RNA isolation & purification market estimates and forecasts 2021 - 2033 (USD Million)
  • 5.4.2. miRNA Isolation & Purification
    • 5.4.2.1. miRNA isolation & purification market estimates and forecasts 2021 - 2033 (USD Million)
  • 5.4.3. mRNA Isolation & Purification
    • 5.4.3.1. mRNA isolation & purification market estimates and forecasts 2021 - 2033 (USD Million)
  • 5.4.4. Total RNA Isolation & Purification
    • 5.4.4.1. Total RNA isolation & purification market estimates and forecasts 2021 - 2033 (USD Million)
  • 5.4.5. Other
    • 5.4.5.1. Other market estimates and forecasts 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Segment Dashboard
• 6.2. Nucleic Acid Isolation and Purification Market: Application Movement Analysis
• 6.3. Precision Medicine
  • 6.3.1. Precision medicine market estimates and forecasts 2021 - 2033 (USD Million)
• 6.4. Diagnostics
  • 6.4.1. Diagnostics market estimates and forecasts 2021 - 2033 (USD Million)
• 6.5. Drug Discovery & Development
  • 6.5.1. Drug discovery & development market estimates and forecasts 2021 - 2033 (USD Million)
• 6.6. Agriculture and Animal Research
  • 6.6.1. Agriculture and animal research market estimates and forecasts 2021 - 2033 (USD Million)
• 6.7. Other Applications
  • 6.7.1. Other applications market estimates and forecasts 2021 - 2033 (USD Million)

Chapter 7. Method Business Analysis

• 7.1. Segment Dashboard
• 7.2. Nucleic Acid Isolation and Purification Market: Method Movement Analysis
• 7.3. Column Based
  • 7.3.1. Column based medicine market estimates and forecasts 2021 - 2033 (USD Million)
• 7.4. Magnetic Beads
  • 7.4.1. Magnetic beads market estimates and forecasts 2021 - 2033 (USD Million)
• 7.5. Reagent Based
  • 7.5.1. Reagent based market estimates and forecasts 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others market estimates and forecasts 2021 - 2033 (USD Million)

Chapter 8. End Use Business Analysis

• 8.1. Segment Dashboard
• 8.2. Nucleic Acid Isolation and Purification Market: End Use Movement Analysis
• 8.3. Academic Research Institutes
  • 8.3.1. Academic research institutes market estimates and forecasts 2021 - 2033 (USD million)
• 8.4. Pharmaceutical and Biotechnology Companies
  • 8.4.1. Pharmaceutical and biotechnology companies market estimates and forecasts 2021 - 2033 (USD Million)
• 8.5. Contract Research Organizations
  • 8.5.1. Contract research organizations market estimates and forecasts 2021 - 2033 (USD Million)
• 8.6. Hospitals and Diagnostic Centers
  • 8.6.1. Hospitals and diagnostic centers market estimates and forecasts 2021 - 2033 (USD Million)
• 8.7. Other End-use
  • 8.7.1. Other end-use market estimates and forecasts 2021 - 2033 (USD Million)

Chapter 9. Regional Business Analysis

• 9.1. Regional Market Share Analysis, 2025 & 2033
• 9.2. Regional Market Dashboard
• 9.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 9.4. North America
  • 9.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Competitive scenario
    • 9.4.2.3. Regulatory framework
    • 9.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Competitive scenario
    • 9.4.3.3. Regulatory framework
    • 9.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Competitive scenario
    • 9.4.4.3. Regulatory framework
    • 9.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 9.5. Europe
  • 9.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Competitive scenario
    • 9.5.2.3. Regulatory framework
    • 9.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Competitive scenario
    • 9.5.3.3. Regulatory framework
    • 9.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Competitive scenario
    • 9.5.4.3. Regulatory framework
    • 9.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Competitive scenario
    • 9.5.5.3. Regulatory framework
    • 9.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Competitive scenario
    • 9.5.6.3. Regulatory framework
    • 9.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.7. Norway
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Competitive scenario
    • 9.5.7.3. Regulatory framework
    • 9.5.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key country dynamics
    • 9.5.8.2. Competitive scenario
    • 9.5.8.3. Regulatory framework
    • 9.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.9. Denmark
    • 9.5.9.1. Key country dynamics
    • 9.5.9.2. Competitive scenario
    • 9.5.9.3. Regulatory framework
    • 9.5.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Competitive scenario
    • 9.6.2.3. Regulatory framework
    • 9.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Competitive scenario
    • 9.6.3.3. Regulatory framework
    • 9.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Competitive scenario
    • 9.6.4.3. Regulatory framework
    • 9.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Competitive scenario
    • 9.6.5.3. Regulatory framework
    • 9.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Competitive scenario
    • 9.6.6.3. Regulatory framework
    • 9.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Competitive scenario
    • 9.6.7.3. Regulatory framework
    • 9.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 9.7. Latin America
  • 9.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Competitive scenario
    • 9.7.2.3. Regulatory framework
    • 9.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Competitive scenario
    • 9.7.3.3. Regulatory framework
    • 9.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 9.8. MEA
  • 9.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Competitive scenario
    • 9.8.2.3. Regulatory framework
    • 9.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Competitive scenario
    • 9.8.3.3. Regulatory framework
    • 9.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key country dynamics
    • 9.8.4.2. Competitive scenario
    • 9.8.4.3. Regulatory framework
    • 9.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key country dynamics
    • 9.8.5.2. Competitive scenario
    • 9.8.5.3. Regulatory framework
    • 9.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2025
• 10.4. Company Profiles/Listing
  • 10.4.1. QIAGEN
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Thermo Fisher Scientific, Inc.
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Illumina, Inc.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Danaher
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. F. Hoffmann-La Roche Ltd
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Merck KGaA
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Agilent Technologies
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Bio-Rad Laboratories, Inc.
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Takara Bio Inc.
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Promega Corporation
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives